<DOC>
	<DOC>NCT01180530</DOC>
	<brief_summary>This study is conducted in Asia, Europe and North America. The aim of this observational study is to evaluate the safety of NovoPen Echo速 by collecting safety information (incidence of technical complaints related to adverse reactions). Study duration: 12-18 weeks.</brief_summary>
	<brief_title>Observational Study of NovoPen Echo速 on Safety and Treatment Satisfaction in Children and Adolescents With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>Children/adolescents with type 1 diabetes mellitus After the participating physician's decision has been made to initiate treatment with NovoPen Echo速, any patient who meets all the inclusion criteria and does not meet any of the exclusion criteria, is eligible to participate Use of insulin pen or syringes for at least 12 months Insulin pump or Insuflon速 users Any disease or condition in children/adolescents which might interfere with the study at the individual physician's discretion</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>